Compare CNVS & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | TELA |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 51.2M |
| IPO Year | 2003 | 2019 |
| Metric | CNVS | TELA |
|---|---|---|
| Price | $2.41 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.00 | $3.31 |
| AVG Volume (30 Days) | 136.2K | ★ 355.0K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $79,791,000.00 | $77,055,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | $36.06 | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 77.29 | 12.24 |
| 52 Week Low | $2.24 | $0.86 |
| 52 Week High | $7.39 | $3.12 |
| Indicator | CNVS | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 46.54 |
| Support Level | $2.40 | $1.10 |
| Resistance Level | $2.61 | $1.20 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 29.20 | 55.59 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.